LOCALLY ADVANCED TRIPLE-NEGATIVE BREAST CARCINOMA
Clinical trials for LOCALLY ADVANCED TRIPLE-NEGATIVE BREAST CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new LOCALLY ADVANCED TRIPLE-NEGATIVE BREAST CARCINOMA trials appear
Sign up with your email to follow new studies for LOCALLY ADVANCED TRIPLE-NEGATIVE BREAST CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Custom cancer vaccine designed to train your own immune system
Disease control Recruiting nowThis study is testing a new, personalized vaccine designed to teach the body's immune system to recognize and attack a patient's specific cancer. It is being given alongside an existing immunotherapy drug (pembrolizumab) to adults with advanced solid tumors that have spread. The …
Matched conditions: LOCALLY ADVANCED TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Apr 02, 2026 14:58 UTC
-
Doctors test custom cancer vaccine to train immune system
Disease control Recruiting nowThis early-stage trial is testing a new, personalized vaccine for triple-negative breast cancer (TNBC). The vaccine is custom-made from a piece of a patient's own tumor and is designed to teach their immune system to recognize and attack the cancer. Researchers are studying the v…
Matched conditions: LOCALLY ADVANCED TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Scientists test Triple-Threat attack on tough breast cancer
Disease control Recruiting nowThis early-stage trial is testing the safety of a new three-drug combination for people with advanced triple-negative breast cancer. It combines a new experimental pill (ZEN003694) with an immunotherapy drug (pembrolizumab) and a standard chemotherapy (nab-paclitaxel). The main g…
Matched conditions: LOCALLY ADVANCED TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC